Literature DB >> 31724272

Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features.

Anna Hoppmann1, Adele P Williams2, Aubrey Coleman3, Clay Tynes4, Grant R Williams5, Elizabeth Mroczek-Musulman6, Jamie Aye1, Kimberly F Whelan1, Michael R Clay7, Sarangarajan Ranganathan8, Elizabeth A Beierle9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31724272      PMCID： PMC7347293          DOI： 10.1002/pbc.28048

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  13 in total

1.  Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.

Authors:  John D Hainsworth; David R Spigel; Sharlene Litchy; F Anthony Greco
Journal:  J Clin Oncol       Date:  2006-08-01       Impact factor: 44.544

2.  Childhood and adolescent cancer statistics, 2014.

Authors:  Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-31       Impact factor: 508.702

3.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Authors:  C G Moertel; L K Kvols; M J O'Connell; J Rubin
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

Review 4.  Utility of immunohistochemistry in the pancreatobiliary tract.

Authors:  Fan Lin; Zongming Eric Chen; Hanlin L Wang
Journal:  Arch Pathol Lab Med       Date:  2015-01       Impact factor: 5.534

5.  Neuroendocrine carcinomas of the pancreas with 'Rhabdoid' features.

Authors:  Maria Delia Perez-Montiel; Wendy L Frankel; Saul Suster
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

Review 6.  Neuroendocrine carcinoma of unknown primary site.

Authors:  David R Spigel; John D Hainsworth; F Anthony Greco
Journal:  Semin Oncol       Date:  2009-02       Impact factor: 4.929

7.  Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors.

Authors:  Andrew C Hoot; Pierre Russo; Alexander R Judkins; Elizabeth J Perlman; Jaclyn A Biegel
Journal:  Am J Surg Pathol       Date:  2004-11       Impact factor: 6.394

8.  Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes.

Authors:  Abbas Agaimy; Florian Haller; Judith Frohnauer; Inga-Marie Schaefer; Philipp Ströbel; Arndt Hartmann; Robert Stoehr; Günter Klöppel
Journal:  Mod Pathol       Date:  2014-08-08       Impact factor: 7.842

9.  Outcome for children with metastatic solid tumors over the last four decades.

Authors:  Stephanie M Perkins; Eric T Shinohara; Todd DeWees; Haydar Frangoul
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

Review 10.  Neuroendocrine tumor of the pancreas with rhabdoid feature.

Authors:  Tetsuyuki Miyazaki; Shinichi Aishima; Minoru Fujino; Keigo Ozono; Yuichiro Kubo; Yasuhiro Ushijima; Takashi Osoegawa; Eikichi Ihara; Itou Tetsuhide; Takao Ohtsuka; Masafumi Nakamura; Yoshinao Oda
Journal:  Virchows Arch       Date:  2018-06-24       Impact factor: 4.064
View more
  2 in total

1.  Sex differences in associations between birth characteristics and childhood cancers: a five-state registry-linkage study.

Authors:  Lindsay A Williams; Jeannette Sample; Colleen C McLaughlin; Beth A Mueller; Eric J Chow; Susan E Carozza; Peggy Reynolds; Logan G Spector
Journal:  Cancer Causes Control       Date:  2021-07-23       Impact factor: 2.506

Review 2.  Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors.

Authors:  Karolina Nemes; Pascal D Johann; Stefanie Tüchert; Patrick Melchior; Christian Vokuhl; Reiner Siebert; Rhoikos Furtwängler; Michael C Frühwald
Journal:  Cancer Manag Res       Date:  2022-02-09       Impact factor: 3.989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.